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INTRODUCTION
Melatonin is regarded as a natural component of saliva. In
the oral cavity, a number of potential activities related to its anti-
inflammatory and anti-oxidant properties, either receptor
dependent or receptor independent, are discussed (1).
Immunoblotting shows that the rat parotid gland expresses
receptors of melatonin of types MT1 and MT2 (2). On the
administration of melatonin, the gland responds with the acinar
secretion of amylase and the synthesis of secretory proteins, both
phenomena preferentially associated with the MT2 type and the
intracellular activity of NO synthase of the neuronal type (2, 3).
Moreover, using the rat parotid gland as an experimental model,
the lipopolysaccharide-induced inflammatory response of the
gland is markedly reduced by the administration of melatonin
(4). In vitro, fragments of the human parotid gland exposed to
melatonin display ultrastructural changes associated with
secretory activity and analytical pharmacology shows that the
MT2 receptors are preferentially involved (5). In human salivary
glands, light microscopy demonstrates the diffuse cellular
distribution of MT1 and MT2 receptors (6-8). By transmission
electron microscopy (TEM), the subcellular localisation of MT1
and MT2 receptors in human parotid glands in both the cell
membrane and the cytosolic organelles emerges, which led us to
suggest the presence of an active uptake/transport system for
melatonin, linked to its receptors (8).
It could be expected that exposure to increased blood levels
of melatonin would influence the amount and (or) the
distribution pattern of the melatonin receptors in the gland cells.
After having initially confirmed the subcellular distribution of
the two types of melatonin receptor in the rat parotid gland,
similar to that previously described for the human parotid gland
(8), we put our hypothesis to the test by exposing the
anaesthetised rat to a continuous intravenous infusion of
melatonin over a period of two hours. Gland specimens were
processed for TEM, using the gold post-embedding technique,
and for immunoblotting. The secretory granules were the
particular focal point of the microscopic investigation. Our
previous study of the human parotid gland showed that reactivity
for the two types of melatonin receptor was preferentially
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Our recent ultrastructural study of human parotid glands revealed that the melatonin receptors, MT1 and MT2, are
localised in the plasma cell membranes of acinar and ductal cells but also, and intriguingly, predominantly in acinar
secretory granules, giving rise to the working hypothesis that secretory granules are a part of a transcytotic transport
system for melatonin. To put this hypothesis to the test in rat parotid glands, anaesthetised animals were exposed to a
high melatonin dose (3 mg/kg per hour), infused intravenously over two hours and aiming to stimulate a glandular
melatonin-receptor-dependent intracellular transport system, if any. Thirty minutes later, the right parotids were
removed. Pre-stimulation, left parotid gland tissue was removed to serve as (untreated) controls. Gland tissues were
processed for the gold post-embedding technique and for western blot analysis. In untreated glands, on transmission
electron microscope images, melatonin receptors displayed a distribution pattern similar to that in human parotids, i.e.
here, too, the receptors were principally associated with the acinar secretory granules. In melatonin-treated glands, the
number of granules associated with the MT1 receptor was twice that in untreated glands, despite the same total granule
number in the two glands. Moreover, the density of gold particles showing MT1-receptor immunoreactivity associated
with granules in melatonin-treated glands was 2.5 times that in untreated glands. The number of MT1 receptors
associated with the granule membrane was about three times higher in melatonin-treated glands than in untreated glands,
while the number of MT1 receptors inside the granules was about twice that in untreated glands. The immunoblotting
of membrane-enriched samples showed that the MT1-receptor expression was about three times that of untreated glands.
When it came to the MT2 receptor, no changes were observed. Melatonin itself thus exerts dynamic effects on its MT1
receptor, which may reflect an adaptive receptor-linked carrier system for melatonin, delivering - upon gland stimulation
- melatonin to the saliva by exocytosis.
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localised in the granules. Moreover, the granules are the most
representative organelle in the serous cells and, further, they
have a distinct membrane border. Our present study showed that
the two types of melatonin receptor differ in their response to
melatonin administration, implying that they perform different
functional roles.
MATERIAL AND METHODS
The in-vivo experiments were approved by the Ethics
Committee for Animal Experiments (CESA), University of
Cagliari, Italy. A total of seven adult, female Sprague-Dawley
rats, weighing between 260 g and 310 g, were used. The rats
were housed at a constant temperature with light-dark cycles of
12 hours, lights on at 6 am and off at 6 pm. The rats were
maintained on a pelleted standard diet and tap water ad libitum.
The experiments were performed between 9 am and 1 pm.
In-vivo experiments
The animals were anaesthetised with 0.5 ml/100 g of
equitesin intraperitoneally (9). The body temperature of the
anaesthetised animal, measured with a rectal probe, was
maintained at 38°C by means of a thermostatically controlled
blanket. The animals were fitted with a femoral venous
polyethylene catheter, which served as a conduit for the infusion
of melatonin, and a tracheal cannula. Prior to the start of the
infusion, the left parotid gland was removed to serve as
(untreated) control tissue; bleeding, if any, was stopped by
Spongostan™. The wound was then sutured. Melatonin (3
mg/kg per hour) was intravenously infused continuously over a
period of two hours. Thirty minutes after the end of the infusion
period, the corresponding right gland was removed. From each
parotid gland, specimens were taken for electron microscopy
and immunoblotting. Whereas the specimens for microscopy
were prepared immediately following the removal of the gland
(see below), those for immunoblotting were frozen and kept at
–70°C until homogenised (see below). The animals were killed
by an overdose of equitesin.
Transmission electron microscopy
Samples were cut into small pieces and fixed for two hours
with a mixture of 3% paraformaldehyde and 1% glutaraldehyde
in 0.1 M cacodylate buffer (10). They were then rinsed in
cacodylate buffer supplemented with 3.5% sucrose, dehydrated
and embedded in Epon resin (glycide ether 100). In order to
preserve the antigenicity of the tissue, osmium tetroxide was
omitted in the preparation of immunocytochemical samples.
Ultrathin sections (80 nm) were collected on nickel grids and
processed for the immunohistochemical analysis. For MT1
immunolocalisation, the grids were treated with 1% bovine
serum albumin (BSA) and 5% normal goat serum (NGS) in
phosphate-buffered saline (PBS) solution to block non-specific
binding. They were then incubated over night at 4°C with a
rabbit polyclonal antibody anti-melatonin receptor 1, diluted
1:50 in 1% BSA and 5% NGS. The grids were then incubated for
one hour at room temperature with the secondary antiserum, a
goat anti-rabbit IgG conjugated to 15 nm gold particles, diluted
1:50 in 1% BSA-PBS. For MT2, the grids were treated with 1%
bovine serum albumin (BSA) and 5% normal rabbit serum
(NRS) in phosphate-buffered saline (PBS) solution to block non-
specific binding. They were then incubated over night at 4°C
with anti-MT2 goat polyclonal antibody diluted 1:50 in 1% BSA
and 5% NRS. The grids were then incubated for one hour at
room temperature with the secondary antiserum, a rabbit anti-
goat IgG conjugated to 10 nm gold particles, diluted 1:50 in 1%
BSA-PBS. After washing, they were stained with uranyl acetate
and bismuth subnitrate, after which they were finally observed
and photographed in a JEOL 100S transmission electron
microscope. Micrographs were acquired by TEM in different
parts of the grid that were randomly chosen. Fragments were
also incubated with a non-immune serum or omitting the
primary antibody.
Immunoblotting
Parotid glands were homogenised, following a standard
procedure for membrane protein isolation (11). Briefly, tissues
were homogenised in the homogenising buffer (10 mM Tris pH
7.4, 0.32 M sucrose, 5 mM EDTA), with the addition of 1:100
protein inhibitor cocktail, centrifuged at 1000 g for 20 min (in
order to eliminate nuclei and large-scale cellular debris), after
which the supernatant was centrifuged at 12,000g for 20 min.
The resulting pellet was washed three more times in the same
buffer. It mainly represents plasma membranes, membranes of
granules and endocytic vesicles and similar sized organelles that
precipitate in the range of 2500–12,000 g (12, 13). Protein
determination was obtained using the Lowry method. Samples
(50 µg) were loaded into 4 – 15% Mini-PROTEAN® TGX™
precast polyacrylamide gels and allowed to run at 80V for 1.5 h.
Gels were blotted onto PVDF membranes and blotted
membranes were blocked with 5% milk in Tris buffered saline
with 0.1% Tween 20 (TBS-T) for two hours. The incubation of
primary antibodies against MT1 or MT2 receptors (dilution
1:300 in TBS-T with 5% milk) followed over night at 4°C.
Secondary antibodies (goat anti-rabbit peroxidase conjugate
1:5000, for MT1, or rabbit anti-goat peroxidase conjugate
1:3000, for MT2, both from Sigma-Aldrich, St. Louis, MO,
USA) were incubated for two hours at room temperature.
Immunoreactive bands were detected using the ECL Prime
chemiluminescence kit and images were acquired using a
Fujifilm Luminescent Image Analyzer LAS4000 System
(Fujifilm, Tokyo, Japan). The densitometry of immunoreactive
bands was analysed by Image Studio Lite Software (LI-COR,
Nebraska, USA). Receptor quantification was expressed as the
ratio between the relative intensity of receptor signals and the
expression of the housekeeping gene for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). In fact, our protein
extracts enriched with membrane proteins also contained
GAPDH, as revealed by incubation with 1:1,000 rabbit anti-
GAPDH antibody (Sigma-Aldrich, St. Louis, MO, USA),
followed by 1:5,000 goat anti-rabbit peroxidase conjugate.
Chemicals
The Epon resin was purchased from Merck (Darmstadt,
Germany), the rabbit polyclonal antibody anti-melatonin
receptor 1 from Biorbyt (Cambridge, Cambridgeshire, UK) and
the goat anti-rabbit IgG from GE Healthcare (Milan, Italy). The
goat antibody anti-melatonin receptor 2 and the rabbit anti-goat
IgG were purchased from Santa Cruz Biotechnology (Dallas,
Texas, USA), the Mini-PROTEAN® TGX™ precast
polyacrylamide gels from Biorad (CA, USA) and the PVDF
membranes and ECL Prime chemiluminescence kit from GE
Healthcare (NJ, USA). The other chemical substances and drugs
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Statistical analysis
The quantitative analysis of labelling density was performed
with Image Tool for Windows (University of Texas Health
Science Center in San Antonio) and with Image Pro Plus (Media
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Cybernetics, Silver Spring, MD, USA). Image analysis was
performed on a total of 36 micrographs, randomly acquired by
TEM, 18 images for untreated specimens and 18 for melatonin-
treated specimens. MT1-receptor immunoreactivity was
searched for in 382 granules of untreated specimens and in 499
granules of melatonin-treated specimens, while the
corresponding figures were 491 and 342 with respect to MT2-
receptor immunoreactivity. The data are expressed as the mean
labelling density (i.e. number of gold particles of granules per
µm2). Moreover, the number of immunolabelled MT1 receptors
associated with the membrane part of the granules and the
content of the granules respectively were determined. The gold
particles directly localised on the membrane and those within a
range of about ± 25 nm (related to the membrane) were
considered to be associated with the membrane. The gold
particles localised further away, and inside the granule, were
considered to be associated with granule content.
The immunoblotting data for MT1 and MT2 receptors of
both untreated and melatonin-treated glands were normalised to
the mean value of the untreated glands for the respective
receptor type, set at 100 percent.
The Shapiro-Wilk test was used to determine the distribution
pattern of the samples. For non-normal distribution, the
statistical significance of differences was calculated using the
Mann-Whitney U-test for two groups and the Kruskal-Wallis
one-way of analysis and Dunn's post-hoc test were used for
multiple comparisons. For normal distribution, the unpaired
Student's two-tailed t-test was used. Statistical significances
were calculated on raw data. Probabilities of < 5% were
considered significant.
RESULTS
MT1- and MT2-receptor labelling in untreated glands
The parotid glands expressed immunoreactivity for both
MT1 (Fig. 1a) and MT2 receptors (Fig. 1b). The intracellular
localisation of MT1 reflected that of MT2, although the MT1
staining was weaker. The preferential site for the reactivity of the
two types of receptor was the acinar secretory granules, where
they appeared in both the membranous and the cytosolic parts of
the granule. Small positive vesicles were observed throughout
the cytoplasm and, in particular, surrounding the granules (Fig.
2a). Moreover, the basolateral cell membranes were also marked
for both MT1 (Fig. 2b) and MT2 receptors.
In the duct cells of the intercalated segments, immunoreactivity
was occasionally detected for both MT1 and MT2 receptors (Fig.
3a). Few positive MTl vesicles were found, principally near the
apical area. In the striated duct cells, few marked vesicles were
observed next to the apical compartment, but most of the MT1-
positive vesicles were located close to the basal compartment, or in
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Fig. 1. Secretory granules of
acinar serous cells in
untreated parotid gland. (a)
The gold particles marking
the MT1 receptor were
retrieved in a restricted
number of secretory
granules (G). (b) The gold
particles indicating the MT2
receptor, on the other hand,
occurred more frequently.
The asterisks and inset show
the MT2-receptor reactivity
on the lateral membrane. L,
lumen; Bars, 1 µm.
Fig. 2. Portions of acinar
serous cells in untreated
parotid gland staining for
the MT1 receptor. The
MT1 receptor was
observed in small vesicles
(a, arrows) among the
secretory granules and in
the basal membrane (b,
asterisks). The vesicles
limiting membranes are not
so contrasted due to the
omission of osmium
tetroxide in order to
preserve the antigenicity of
the tissue. Inset: a detail of
basal membrane labelled
for MT1 receptors. G,
granules; Bars, 1 µm.
the basolateral folds, which are the most representative feature of
this ductal portion. In all these parts of the ductal system, the
granules were always unstained. The MT2 receptor showed the
same distribution pattern in the striated ducts as the MT1 receptor,
although the presence of gold particles for MT2 was more frequent
(Fig. 3b). Occasionally, the nuclei and mitochondria of acinar and
duct cells were decorated with gold particles showing reactivity for
the two receptor types. None of the samples, where the primary
antibody was omitted, exhibited positivity (Fig. 4a, 4b); a lack of
positivity was also seen when non-immune serum was used.
MT1- and MT2-receptor labelling in melatonin-treated glands
The pattern of MT1- and MT2-receptor staining appeared
unchanged in melatonin-treated parotids in relation to untreated
ones. As in the untreated glands, the preferential site for gold
particle deposition was the secretory granules of the acinar cells
in the melatonin-treated glands. However, a quantitative
assessment revealed changes in response to melatonin not only
in the number of gold particles deposited on the granule
membrane and inside the granule but also in the number of
stained granules.
Morphometric evaluation of untreated and melatonin-treated
glands
In the glands exposed to melatonin, the density of the secretory
granules did not differ (unpaired two-tailed t-test) from that of the
secretory granules of the contralateral glands removed before the
infusion of melatonin, where the total number of granules was 45.2
± 3.5 and 47.7 ± 4.2 per 100 µm2 of cell area in MT1-receptor-
labelled samples and 45.4 ± 2.5 and 43.4 ± 3.5 per 100 µm2 of cell
area in MT2-receptor-labelled samples respectively.
1. The MT1 receptor
The granule population stained for the MT1 receptor was
45% (223 of 499) in the melatonin-treated gland and 25% (94
of 382) in the untreated gland, i.e. almost twice as many
granules showed reactivity for the MT1 receptor after the
infusion of melatonin (Fig. 7). The labelling density of gold
particles showing immunoreactivity for the MT1 receptor
associated with the granules (Fig. 5) was higher (P < 0.001,
Kruskal-Wallis test, Fig. 6a) in the treated glands (1.21 ± 0.1
per µm2, total number of granules examined: 499) than in the
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Fig. 3. Untreated parotid
gland. (a) Intercalated duct
cells (ID). A few positive
vesicles showing MT1
receptors (arrowheads) were
found, principally near the
apical area, while the
granules of this ductal
portion were unstained for
MT1. Similarly, a few gold
particles indicating MT2
receptors were sporadically
observed in these cells
(photo not shown). 
(b) Striated duct cells. The
gold particles indicating the
MT2 receptor decorated the
basolateral membrane
(arrows) and often appeared
in association with small
vesicles (arrowheads). 
A similar distribution was
observed for MT1 receptors
(photo not shown). L,
lumen; Bars, 1 µm.
Fig. 4. Specimens incubated
without primary antiserum.
The acinar serous cells
completely lacked staining
for MT1 (a) and MT2 (b)
receptors. L, lumen; Bars, 1
µm.
untreated glands (0.48 ± 0.05 per µm2, total number of granules
examined: 382). In the melatonin-treated glands, the mean
number of MT1 receptors located on the membrane part of the
granule (Fig. 6b) was about three times higher than that of MT1
receptors located on the membrane part of the granule in the
untreated glands (0.24 ± 0.03 versus 0.07 ± 0.01 respectively; P
< 0.001, Mann-Whitney U-test). Similarly, in the treated glands,
the mean amount of MT1-receptor reactivity located on the
inner side of the granules (Fig. 6b) was about twice that in the
corresponding part of the untreated glands (0.79 ± 0.08 versus
0.35 ± 0.05 respectively; P < 0.001, Mann-Whitney U-test).
2. The MT2 receptor
The granule population stained for the MT2 receptor in the
melatonin-treated glands (68%: 233 of 342) did not differ from
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Fig. 6. Morphometric
evaluation of the MT1- and
MT2-receptor labelling
density in untreated glands
and in melatonin (mel)-
treated glands; (a) number
of gold particles per µm2 of
the granules expressed as
mean labelling density ±
S.E.M, (b) mean number of
gold particles for MT1
receptors related to all
observed granules, in
untreated and mel-treated
glands, associated with the
membrane part and with
the content of the granules.
*** P < 0.001.
Fig. 5. Portions of serous cell stained for MT1
receptors in untreated (a) and (b) melatonin-
treated glands and for MT2 receptors in
untreated (c) and (d) melatonin-treated glands.
The number of MT1-stained secretory granules
appeared more numerous in the treated glands.
Moreover, the granule membranes (arrows)
appeared more decorated. With respect to the
MT2 receptor, the number of gold particles in
treated glands appeared not to differ from that
of untreated samples. L, lumen; Bar, 1 µm.
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Fig. 8. Immunoblotting of membrane-enriched samples from
untreated and melatonin (mel)-treated parotid glands. Both
samples showed the presence of MT1 (a, c) and MT2 (b, c)
receptors, but melatonin infusion caused a marked increase
in MT1-receptor expression, whereas MT2-receptor
expression was unchanged. The housekeeping protein,
GADPH, served as a reference against which the target
proteins were normalised in order accurately to quantify
fluorescent western blots. Mean values ± S.E.M. * P < 0.05.
Fig. 7. Percentage of the MT1- and MT2-
labelled granules in untreated and melatonin
(mel)-treated glands related to all observed
granules. The morphometric evaluation
revealed that melatonin stimulation increased
the number of granules labelled for MT1 but
not for MT2.
that in the untreated ones (67%: 327 of 491) (Fig. 7). In the
untreated glands, the labelling density of gold particles
associated with the secretory granules and showing reactivity for
the MT2 receptor was about five times higher than that for the
MT1 receptor (P < 0.001, Kruskal-Wallis test). In treated glands,
the labelling density of gold particles associated with the
secretory granules and showing reactivity for the MT2 receptor
was about two times higher than that for the MT1 receptor (P <
0.001, Kruskal-Wallis test). In contrast to the MT1 receptor, the
density of the MT2 receptor was not affected in a statistically
significant way (Kruskal-Wallis test) by melatonin exposure and
was 2.3 ± 0.1 per µm2 (n = 342) versus a mean value for
untreated glands of 2.6 ± 0.2 per µm2 (n = 491).
Immunoblotting analysis
The immunoblotting of membrane-enriched samples from
the glands revealed the presence of both MT1 and MT2 receptors.
In samples of untreated glands, optical densitometry data,
normalised for GAPDH expression, were 0.09 ± 0.03 for MT1
and 0.20 ± 0.09 for MT2 (arbitrary units). After melatonin
treatment, the expression of MT1 receptors was about three times
that of the untreated gland, i.e. 0.27 ± 0.06 (P < 0.05, unpaired
two-tailed t-test). The immunoblotting for MT2 receptors
revealed a fairly constant signal in the membranous fraction
before and after (0.22 ± 0.046) melatonin infusion (Fig. 8).
DISCUSSION
As judged by the distribution of gold particles, the two types
of melatonin receptor in the rat parotid gland displayed a pattern
similar to that previously reported for the human parotid gland
(8). Although present at the level of the cell membrane, their
predominant localisation was the acinar secretory granules and,
in addition, the small vesicles among these granules. Moreover,
they were also associated with vesicles of the ductal cells.
However, in contrast to the human parotid gland, the number of
gold particles in the rat parotid gland showing immunoreactivity
for the MT1 receptor was smaller than those showing
immunoreactivity for the MT2 receptor.
Melatonin has previously been found to cause the in-vivo
secretion of amylase/protein from the rat parotid gland, a
phenomenon probably associated with granule exocytosis (2).
This assumption is supported by the recent ultrastructural
findings of exocytotic events in human parotid tissue exposed to
melatonin in vitro (5). In the present study, however, no support
for acinar degranulation was found. The density of granules was
the same in melatonin-treated glands and untreated glands, a fact
that simplifies comparisons between the two glands. The current
dose exposure per unit of time was probably not high enough to
reach the threshold for evoking granule secretion, although the
blood level of melatonin achieved by the current intravenous
infusion was much higher than can be expected to cause blood
levels of melatonin in rats near physiological amounts (14). The
protocol used did, however, produce reproducible data
demonstrating dynamic effects on the melatonin-receptor
population of potential physiological and pharmacological
importance.
In the acinar cells of parotid glands, an increased load of
circulating melatonin was found to be accompanied by an increase
in the density of immunogold particles signalling the MT1-
receptor type but not of those signalling the MT2-receptor type.
The dissection of the MT1-receptor response showed not only
more granules stained with immunogold particles but also an
increased number of immunogold particles per granule.
Furthermore, this increase involved particles located both in the
membrane of the granule, probably reflecting the membrane
affinity of the G-protein receptor, and its content, which was three
and two times that of untreated glands respectively. Additional
support for the increased localisation of the MT1 receptor to
membranes in response to melatonin was obtained from the
immunoblotting study, showing a threefold increase in
immunoreactivity compared with the value for untreated glands;
here, too, the immunoreactivity of the MT2 receptor remained
unchanged. It should, however, be pointed out that the membrane-
enriched extract of the gland prepared for the immunoblotting
technique represents membranes from various sources, including
plasma membranes and membranes of intracellular organelles,
such as granules, vesicles and mitochondria.
The two types of melatonin receptor belong to the family of
G-protein-coupled, seven transmembrane receptors (15).
Although the cell-membrane location of this receptor family was
initially the focal point, there are now numerous reports showing
intracellular locations of G-proteins and, further, that these
proteins translocate between various sites upon stimulation.
Agonist exposure of the G-protein receptors over a period of
minutes or hours induces receptor internalisation, as a part of
acute receptor desensitisation, and trafficking (16, 17). With
respect to the two types of melatonin receptor, they do not
respond uniformly and, as a result, one receptor type may be
internalised while the other is not; factors of importance to
differences are the melatonin concentration, the time of exposure
and cell types under study (18). Although the possibility cannot
be excluded that the present increase in the density of the MT1
receptor associated with the secretory granules is part of a
desensitising process in response to elevated blood levels, it is
possible that the receptor is involved in the uptake and transport
of melatonin that is to be stored in the secretory granules.
Acinar small vesicles, distributed throughout the granules
and nearby basolateral membranes, displayed reactivity for the
melatonin receptors. In the present study, neither the number of
vesicles nor the number of the two types of melatonin receptor
associated with the vesicles was calculated. Although the
vesicles may perform a number of functions in the cells (19), it
is tempting, in line with our hypothesis, to suggest that the
presence of reactivity for the melatonin receptors associated with
the small vesicles reflects the trafficking of the melatonin-
receptor complex from the plasma membrane either towards the
secretory granules or directly towards the glandular lumen; the
latter pathway also perhaps serves as an explanation of the
presence of reactive vesicles in the ductal cells.
In previous work by Bubenik (20), melatonin has been
demonstrated in the palate salivary glands of the rat and, further, in
the stomach, duodenum and colon of this species (21). However, as
pointed out by Bubenik (22), the immunofluorescence method
used does not permit a distinct description of the distribution of the
melatonin-positive cells or their cellular localisation. In the human
acinar cells of the parotid gland, support for the granular storage of
melatonin has recently been obtained (23).
Hypothetically, inside the granule, the anti-oxidant effect of
melatonin may contribute to the protection of the various
constituents of the granule, including the various enzymes. Upon
granule exocytosis, released melatonin may exert a number of
beneficial effects in the oral cavity in the event of caries, ulcers,
periodontal diseases and candidiasis (24). The presence of
melatonin in the saliva is usually attributed to the passive
passage of the non-protein bound fraction, from the blood to the
oral cavity, thus reflecting the blood levels of melatonin (1, 25-
28). The intestinal tract may both synthesise melatonin and act
as a sink for pineal gland-derived melatonin (14, 29). As a result,
particularly during the night, when the blood level of melatonin
is high, the salivary glands may take up and store melatonin in
the secretory granules via the MT1 receptor. Subsequently, upon
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the reflex stimulation of the glands, melatonin may be released
by the regulated secretory pathway (30). In this connection it
may be mentioned that a melatonin synthesis has been suggested
to occur in salivary duct cells and possibly melatonin may exert
paracrine effects in the acinar cells via its receptors (31).
Likewise, in the rat thyroid gland a paracrine secretion of
melatonin was suggested. C-cell secreted melatonin seems to
influence the activity of follicular cells within the gland (32).
Interestingly, in vitro studies of prostate cancer cells suggest
that melatonin crosses the cell membrane and reaches
cytoplasmic and nuclear compartments by active transport or
facilitated diffusion rather than by simple passive diffusion due
to the amphiphilic nature of melatonin (33); in this case, glucose
transporters, in particular GLUT1, were suggested as a carrier of
melatonin (34). Transcytotic receptor-mediated passages over
acinar cells have, for example, been demonstrated with respect
to immunoglobulin A and transferrin (35, 36). As is the case for
immunoglobulin A and transferrin, once in the saliva, melatonin
is supposed to separate from its transporter.
The infusion time for melatonin in the present study was two
hours, followed by a 30-minute post-infusion period. There is thus
a possibility that a minor fraction of the MT1-receptor population
represents newly synthesised MT1 receptors (37). The present
study, combined with our previous observations (2, 3, 5), may, at
first sight, suggest that the two types of receptor are potentially
involved in different functions in the gland, the MT1 receptor in
the transport and granular storage of melatonin and the MT2
receptor in the secretion of amylase/protein and the synthesis of
secretory proteins. Nevertheless, it should be remembered that, in
this study, M2 receptors also occurred in association with the
secretory granules and the vesicles; in fact, this type of receptor
was in the majority, at least when its association with the secretory
granules was counted. Although the MT2 receptors were not
influenced by the melatonin infusion in the current experimental
conditions, a role for this type of receptor in melatonin transport
cannot be excluded. Perhaps the MT2 receptor, in contrast to the
MT1 receptor, represents a slowly adapting transport system or is
only mobilised in physiological conditions. It is interesting to
question whether, in physiological conditions, increased glandular
activity evoked by autonomic innervation stimulates intracellular,
melatonin-receptor-linked melatonin transport and, further,
whether pharmacological doses of melatonin, by the MT1-
receptor-mediated translocation of the hormone, may be of
importance in situations in which salivary gland functions fail.
To conclude, an increased load of circulating melatonin
selectively induced an increase in the number of MT1 receptors
(but not of MT2 receptors) associated with the acinar secretory
granules, suggesting a functional role for MT1 receptors in the
salivary gland transport, storage and secretion of melatonin. In
order to obtain further support for this concept, future studies, in
our rat model, have to show a parotid gland output of melatonin
into the saliva that gradually decreases upon prolonged autonomic
receptor stimulation (during constant blood levels of melatonin)
concomitantly with the depletion of the gland content of
melatonin. Further, pre-treatment with melatonin receptor
antagonists and, as judged from the present study, particularly
those involving the MT1 receptor, should prevent melatonin from
accumulating in the gland. When exploring the effect of melatonin
antagonists it should be noted that currently there is no selective
MT1 receptor on the market; comparisons have to be made
between the effects of the non-selective antagonist luzindole and
the selective MT2 receptor antagonist 4-P-PDOT (38).
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